Morning Glory Sciences– Author –
-
What Bispecifics Really Are: 3 Lenses Across History, Definition, and Classification | Bispecific Antibody Drug Series A1
Bispecific antibody drugs are now one of the most important themes in the evolution of cancer therapy and antibody therapeutics. Bispecific antibody drugs are now one of the most important themes in the evolution of cancer therapy and an... -
Mapping Bispecifics in 6+6 Layers: 3 Lenses Setting Up the Series | Bispecific Antibody Drug Series A0
Bispecific antibody drugs have become one of the most prominent areas in cancer therapy over the past several years. Bispecific antibody drugs have become one of the most prominent areas in cancer therapy over the past several years. If ... -
The Full Picture of CAR-T: A Beginner-to-Expert Series Overview (8 Modules That Trace the Field)
This article serves as the complete index page for the CAR-T series now that the series has been completed. This article serves as the complete index page for the CAR-T series now that the series has been completed. What you will learn W... -
Where CAR-T’s Winning Commercialization Strategy Lies: 4 Implementation Axes — COGS, Supply Chain, Site, Regulation | Frontier of Therapy Series | CAR-T B6 [Expert]
In A5 and B5, we explored how in vivo CAR-T is emerging not simply as a novel scientific idea, but as a possible answer to the structural problems of manufacturing, logistics, and access. In A5 and B5, we explored how in vivo CAR-T is em... -
Why Is CAR-T So Expensive? Reading 3 Cost Drivers in Manufacturing & Access — and the Future Reshaped by Next-Gen Tech | Frontier of Therapy Series | CAR-T A6 [Beginner]
CAR-T therapy is one of the cancer treatments that has attracted particularly strong expectations in recent years. CAR-T therapy is one of the cancer treatments that has attracted particularly strong expectations in recent years. In fact... -
Where In Vivo CAR’s Hardest Problems Live: 4 Implementation Axes — Delivery, Control, Safety, CMC/Reg | Frontier of Therapy Series | CAR-T B5 [Expert]
If you want the beginner version first:→ A5: What is in vivo CAR? If you want the beginner version first:→ A5: What is in vivo CAR? “Making CAR cells inside the body” explained simply What you will learn Executive summary1) Delivery: the... -
What Is In Vivo CAR? Reading the Next-Gen Approach of Making CAR Cells Inside the Body Through 3 Mechanisms | Frontier of Therapy Series | CAR-T A5 [Beginner]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A4: Why CAR-T Is Expanding Beyond Cancer (Autoimmunity as an Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index... -
Where Autoimmune CAR-T Is Heading: Design Logic of CD19, BCMA, mRNA CAR and 4 Axes of Company Activity | Frontier of Therapy Series | CAR-T B4 [Expert]
Prefer the overview first?→ A4: Why CAR-T expands beyond cancer (autoimmunity as “reset”) Prefer the overview first?→ A4: Why CAR-T expands beyond cancer (autoimmunity as “reset”) What you will learn Executive summary1) The coordinate sy... -
Why CAR-T Is Expanding Beyond Cancer: Reading 3 Logics of Autoimmune Reset from First Principles | Frontier of Therapy Series | CAR-T A4 [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index New here?→ A0: What is CAR-T therapy? The big picture + index What you will learn The short answer: the appeal is “reset,” not chronic suppression1) What “autoimmunity” means ... -
Oncology Drug Approval News Flash FDA approves nivolumab (Opdivo) with AVD chemotherapy for previously untreated advanced classical Hodgkin lymphoma (and converts prior accelerated approvals in relapsed/refractory cHL to traditional approval)
On March 20, 2026, the U.S. FDA approved nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and pediatric patients aged 12 years and older with previously untreated, Stage III or IV classica... -
Where Solid-Tumor CAR-T Is Heading: 4 Breakthrough Axes — Multi-Target, Logic Gates, Armoring, and Local Delivery | Frontier of Therapy Series | CAR-T B3 [Expert]
Prefer the beginner overview first?→ A3: Why solid tumors are hard for CAR-T (the 3 barriers) Prefer the beginner overview first?→ A3: Why solid tumors are hard for CAR-T (the 3 barriers) What you will learn Executive summary1) The core ... -
Why Solid Tumors Are Hard for CAR-T: Reading the 3 Barriers That Define Today’s Clinical Bottleneck | Frontier of Therapy Series | CAR-T A3 [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) What yo... -
Current Standing of CAR-T Toxicity Management: 5 Implementation Challenges Across Site Ops, Long-Term Safety, and Regulation | Frontier of Therapy Series | CAR-T B2 [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A2: CAR-T side effects without panic (what happens, what to m Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + inde... -
How to Read CAR-T Side Effects: A 3-Axis Map of CRS, ICANS, and Cytopenia for Patients Without Panic | Frontier of Therapy Series | CAR-T A2 [Beginner]
New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index→ A1: Where CAR-T Is Used Tod New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Ther... -
FDA-Approved CAR-T Landscape: 7 Products and the Label Logic Behind Their Indications
Eleven CAR-T products have earned FDA approval, each targeting a specific cell, antigen, and disease. A single well-made table is worth a month of white papers—here is how to read it, and where the next approvals will land. Prefer the be... -
Where CAR-T Is Used Today: Reading the Indication Map Through 5 Blood Cancers and Today’s Standing | Frontier of Therapy Series | CAR-T A1 [Beginner]
New here? If you haven’t read the introduction, it will make this post much easier to follow.→ A0: What Is CAR-T Therapy? The Big Picture + Series Ind New here? If you haven’t read the introduction, it will make this post much easier to ... -
CAR-T at a Glance: A Beginner’s Map of Cells, Targets, and Why It Works
How to use this series (two-layer linkage: Beginner → Expert) This series explains CAR-T therapy in a stepwise way so that readers who are new to the term can first grasp the big picture (Layer A), and then move This series explains CAR-... -
Oncology Drug Approval News Flash FDA approves teclistamab (Tecvayli) plus daratumumab hyaluronidase-fihj for relapsed/refractory multiple myeloma (and converts Tecvayli monotherapy from accelerated to traditional approval)
On March 5, 2026, the U.S. FDA approved teclistamab (Tecvayli), a BCMA×CD3 bispecific antibody, in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least ... -
Cancer Worries Episode 9 — Childhood Cancer: 4 Care Dimensions That Distinguish Pediatric from Adult Oncology
“My child seems unusually tired.” “The fever keeps coming back.” “Bruises appear more easily.” Childhood cancers are uncommon, but once the thought ap “My child seems unusually tired.” “The fever keeps coming back.” “Bruises appear more ... -
Cancer Worries Episode 8 — Brain Tumors: 4 Treatment Crossroads When the Tumor Is Inside the Skull
“My headaches are getting worse.” “I had my first seizure.” “I feel my speech is off.” Brain tumors are emotionally charged, and the fear can escalate “My headaches are getting worse.” “I had my first seizure.” “I feel my speech is off.”...
